Abstract
Maturity-onset diabetes of the young (MODY) is often misdiagnosed as Type I or II diabetes. This study was designedto assess the cost-effectiveness of MODY screening strategies in Hungary, which included a recent genetic testcompared with no routine screening for MODY. A simulation model that combined a decision tree and an individual-level Markov model was constructed to assess the costs per quality-adjusted life yearof screening strategies. Stratifying patients based on age and insulin treatment followed by a risk assessment questionnaire, a laboratory testand genetic testing was the most cost-effective strategy, saving EUR 12 and generating 0.0047 quality-adjusted life years gained per screened patient. This screening strategy could be considered for reimbursement, especially in countries with limited resources.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
